SPRB stock icon

Spruce Biosciences
SPRB

$0.59
1.41%

Market Cap: 24.3M

 

About: Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).

Employees: 22

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 7 analysts
0
News positive %
of 24 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

83% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 12

25% more funds holding

Funds holding: 40 [Q4 2023] → 50 (+10) [Q1 2024]

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

0% more call options, than puts

Call options by funds: $39K | Put options by funds: $39K

35.57% less ownership

Funds ownership: 79.23% [Q4 2023] → 43.67% (-35.57%) [Q1 2024]

67% less funds holding in top 10

Funds holding in top 10: 3 [Q4 2023] → 1 (-2) [Q1 2024]

85% less capital invested

Capital invested by funds: $94.4M [Q4 2023] → $14.1M (-$80.3M) [Q1 2024]

Research analyst outlook

7 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$2
239%
upside
Avg. target
$5.43
820%
upside
High target
$10
1,595%
upside

7 analyst ratings

positive
71%
neutral
29%
negative
0%
Oppenheimer
Hartaj Singh
408%upside
$3
Outperform
Maintained
13 Jun 2024
RBC Capital
Gregory Renza
239%upside
$2
Sector Perform
Downgraded
14 Mar 2024
Leerink Partners
Joseph Schwartz
239%upside
$2
Market Perform
Downgraded
14 Mar 2024
JMP Securities
Jonathan Wolleben
408%upside
$3
Market Outperform
Maintained
14 Mar 2024
RBC Capital
Gregory Renza
1,425%upside
$9
Outperform
Reiterated
5 Mar 2024

Financial journalist opinion

Based on 24 articles about SPRB published over the past 30 days